

Monoclonal Antibody Treatment for COVID-19

Provider Toolkit

Updated October 2021

Contents

- Background
- Provider Resources
- Patient Resources



Background

- This toolkit provides Maryland health care professionals with resources and information on monoclonal antibody treatment for COVID-19.
- Monoclonal antibody treatment (mAb) is not a cure, but it may lessen symptom severity and help keep high-risk patients out of the hospital.



What is Monoclonal Antibody Treatment

 Monoclonal antibodies are laboratory-made proteins that mimic natural antibodies' ability to fight viruses, such as COVID-19.



Who Qualifies for Treatment

There are two indications for monoclonal antibody use.

- 1) Treatment of symptoms of mild-to-moderate COVID-19 in certain high risk individuals.
- 2) Post-exposure prophylaxis in individuals who are not expected have an adequate immune response to COVID-19.



Eligibility for mAb Treatment of COVID-19

mAb treatment is for adults and adolescents (12 and older) who:

- Recently tested positive for COVID-19
- Are within 10 days of first experiencing symptoms
- Do not need to be hospitalized for COVID-19
- Weigh at least 88 pounds

Continued...



Who Qualifies for Treatment

continued

Are in one of the following high-risk categories:

- Are age 55 to 64 AND have cardiovascular disease, hypertension, chronic respiratory diseases or COPD
- Have diabetes, obesity, kidney disease or other serious chronic conditions
- Are 65 years old or older
- Are pregnant
- For adolescents: high BMI, sickle cell disease, heart disease, neurodevelopmental disorders, a medical-related technological dependence, asthma or other chronic respiratory disease
- Or who have been determined by their healthcare provider to be at high risk for worsening and/or hospitalization

Who Qualifies for Post-exposure Prophylaxis

Individuals who have no symptoms, but have been exposed in the past four days to a known or suspected case of COVID-19 and are in one of the following categories:

- Are not fully vaccinated
- Are vaccinated but not expected to have an adequate immune response to the vaccine
- Are in a congregate living situation such as a nursing home or prison



Treatment Locations in Maryland

- There are dozens of monoclonal antibody treatment facilities in Maryland.
- Locations listed on referral form.
- Locations can also be found through the <u>HHS</u>
 website (may not reflect most recent updates).



Referrals for Individuals without PCPs

- Individuals who do not have a healthcare provider may contact <u>eVisit</u> to schedule a virtual appointment.
- Individuals may also <u>self-refer</u>.
- Individuals who do not have access to the internet may call 410-649-6122 and receive information on monoclonal applicability over the phone.



Monoclonal Antibody Treatment for COVID-19

Provider Resources



Provider Resources

Resources for Health Care Professional are available at <u>Information</u> <u>about Monoclonal Antibodies (mAb)</u>



Referral Flyer

Health Care Provider referrals to **Monoclonal Antibody Infusions** Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease mAbs are likely to be most beneficial if given to patients early in symptom • Product delivered via single IV infusion administration • Early evidence suggest promise of mAb products in outpatient settings to reduce hospitalization Adult Process to refer your patients **Eligibility Criteria** 1. Review patient eligibility criteria At least 1 of the for patients with mild-moderate symptoms. following: 1.Age ≥ 65 years; Full criteria listed by FDA: 2.Age ≥ 55 years AND Bamlanivimab and Etesevimab have any of the Casirivimab and Imdevimab following: 2. Perform a COVID-19 PCR or Point-of-Care Cardiovascular Rapid Antigen Test disease (POC Antigen Tests can be supplied by MDH: Hypertension complete this form if interested). COPD/other 3. Refer your positive patients to a partnering 3. Diabetes; infusion site* ASAP 4.Immunosuppressive to start treatment within 10 days of onset of symptoms. Option 1 (Preferred) OR Option 2 5. Receiving immunosuppressive treatment; Send eReferral via the CRISP Complete referral form 6.BMI ≥35; OR **Unified Landing Page** (link at top) and submit (Starter guide: pp. 1-7, 25-35) directly to infusion site disease *(Infusion sites listed on next page)

Maryland

Health Care Provider Referral to Monoclonal Antibody Infusion Overview Flyer



Page 1

Referral Options



Option 1:

CRISP eREFERRAL for Monoclonal Antibody Infusion

Access the CRISP mAb eREFERRAL Starter Guide



Referral Options



Option 2:

Maryland Referral Form for Monoclonal Antibody Infusion Treatment



Point-of-Care Rapid Antigen Testing

- Testing provided to practices willing to identify and refer symptomatic patients eligible for mAb therapy
- Interested practices should fill out this <u>Google Form</u> as soon as possible
- After filling out the form, Maryland Department of Health staff will contact you with next steps
- More information is available <u>here</u>



Federal Resources

- HHS COVID-19 Monoclonal Antibody Therapeutics Digital Toolkit
- HHS Therapeutics Distribution Locations
- <u>Federal Response to COVID-19 Monoclonal Antibody Clinical</u>
 <u>Implementation Guide</u>
- NIH COVID-19 Treatment Guidelines: Antibody Products
- FDA clinical information about mAb therapeutics:
 - Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of REGEN-COV
 - Fact Sheet for Health Care Providers EUA of Bamlanivimab and Etesevimab

Monoclonal Antibody Treatment for COVID-19

Patient Resources



Patient Resources

- FAQs about Monoclonal Antibody Treatment for COVID-19
- Monoclonal Antibody Therapy (mAb) for Treating COVID-19 Fact Sheet
- COVID-19 Monoclonal Antibody Treatment for Older Adults in Nursing Homes
- COVID-19 Monoclonal Antibody Therapeutics
- Monoclonal Antibodies Infographic



Social Media - Twitter







COVID-19 Treatments


Reduce your risk of hospitalization.





Monoclonal Antibody Treatment for COVID-19

Social Media - Facebook





Questions

For more information about mAb, please contact:

Maryland Department of Health Dr. Howard Haft howard.haft@maryland.gov

